Innovating Works
HORIZON-HLTH-2021-DISEASE-04-03
HORIZON-HLTH-2021-DISEASE-04-03: Innovative approaches to enhance poverty-related diseases research in sub-Saharan Africa
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Sólo fondo perdido 0 €
European
This call is closed Esta línea ya está cerrada por lo que no puedes aplicar.
An upcoming call for this aid is expected, the exact start date of call is not yet clear.
Presentation: Consortium Consortium: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Minimum number of participants.
This aid finances Proyectos:

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Health care providers and professionals in sub-Saharan Africa have a better understanding of poverty-related infectious diseases affecting these countries and use new evidences and advanced innovative health technologies or concepts to prevent, treat or diagnose poverty-related infectious diseases in sub-Saharan Africa.Health authorities and health care systems have access to health data and evidences to better develop and implement informed health policies and improved clinical guidelines for health care in sub-Saharan Africa.Health care systems, clinicians and researchers have access to improved clinical research capacities and strengthened infrastructures for clinical research, development and implementation in sub-Saharan Africa, enabling in particular an accelerated development of new, low-cost, easy-to-imp... see more

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Health care providers and professionals in sub-Saharan Africa have a better understanding of poverty-related infectious diseases affecting these countries and use new evidences and advanced innovative health technologies or concepts to prevent, treat or diagnose poverty-related infectious diseases in sub-Saharan Africa.Health authorities and health care systems have access to health data and evidences to better develop and implement informed health policies and improved clinical guidelines for health care in sub-Saharan Africa.Health care systems, clinicians and researchers have access to improved clinical research capacities and strengthened infrastructures for clinical research, development and implementation in sub-Saharan Africa, enabling in particular an accelerated development of new, low-cost, easy-to-implement solutions for improved delivery of medical interventions for vulnerable populations in low-resource settings.More researchers at the early stages of their career (e.g. Master’s, PhD or post-doctoral level) are able to develop their own scientific career in sub-Saharan Africa and/or establish themselves as scientific leaders in sub-Saharan Africa.More clinicians and researchers in sub-Saharan Africa have the capacity to develop and design large-scale studies. Scope:The European and Developing Countries Clinical Trials Partnership (EDCTP) has established itself as the focal point of cooperation in clinical research on infectious disease between the EU and sub-Saharan Africa. To continue these investments after the last calls of the EDCTP2 programme, there is a need to further support research on the major infectious disease threats facing sub-Saharan Africa. Despite large-scale investments in product development for poverty-related infectious diseases (PRDs), progress in achieving public health gain is slow, while sub-Saharan Africa bears the highest burden of these diseases. There is a need to support product development and to encourage the use of new, innovative approaches and emerging technologies in sub-Saharan Africa to achieve rapid progress and impact. The COVID-19 pandemic is generating novel knowledge that could also advance prevention, treatment or diagnosis of PRDs in this part of the world.

Proposals should address all of the following:

Any PRD disease or group of PRDs affecting sub-Saharan Africa (within the scope of EDCTP2[1] or the proposed EDCTP3 and its draft strategic research and innovation agenda[2]).Combine health technologies with other scientific areas such as mobile technologies and digital technologies (mHealth and eHealth), big data processing, and other emerging technologies.Implement one or more medium-scale clinical trials and/or clinical research studies that can deliver the proof-of-concept or validate smart, highly innovative health technologies or concepts to prevent, treat or diagnose PRDs in sub-Saharan Africa, drawing lessons from the COVID-19 experience.Increase collaboration with investors in development cooperation and international partnerships to create solutions for improved development or delivery of medical interventions for vulnerable populations in low-resource settings.Proposals involving pharmaceutical companies and small- or medium-sized enterprises (SMEs) are encouraged.Develop solutions that are easily integrated or linked to existing electronic or digital systems that are used in the implementation of clinical research and health systems’ patient management.Include activities that promote collaboration with ongoing and future EDCTP projects. In this context the granting authority may share project-relevant information with the EDCTP Association and the future EDCTP3 Joint Undertaking.Promote the integration of research work and health care service delivery. [1] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014D0556&from=GA

[2] https://ec.europa.eu/info/sites/info/files/research_and_innovation/funding/documents/edctp3_draft_proposal_14_august_2020.pdf

see less

Temáticas Obligatorias del proyecto: Temática principal: Poverty related diseases Social sciences and humanities International Cooperation Africa Africa Health policy and services

Consortium characteristics

Scope European : The aid is European, you can apply to this line any company that is part of the European Community.
Tipo y tamaño de organizaciones: The necessary consortium design for the processing of this aid needs:

characteristics of the Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Do you want examples? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Financial Chapters: The chapters of financing expenses for this line are:
Personnel costs.
Expenses related to personnel working directly on the project are based on actual hours spent, based on company costs, and fixed ratios for certain employees, such as the company's owners.
Subcontracting costs.
Payments to external third parties to perform specific tasks that cannot be performed by the project beneficiaries.
Purchase costs.
They include the acquisition of equipment, amortization, material, licenses or other goods and services necessary for the execution of the project
Other cost categories.
Miscellaneous expenses such as financial costs, audit certificates or participation in events not covered by other categories
Indirect costs.
Overhead costs not directly assignable to the project (such as electricity, rent, or office space), calculated as a fixed 25% of eligible direct costs (excluding subcontracting).
Madurez tecnológica: The processing of this aid requires a minimum technological level in the project of TRL 4:. Los componentes que integran determinado proyecto de innovación han sido identificados y se busca establecer si dichos componentes individuales cuentan con las capacidades para actuar de manera integrada, funcionando conjuntamente en un sistema. + info.
TRL esperado:

Characteristics of financing

Intensidad de la ayuda: Sólo fondo perdido + info
Lost Fund:
0% 25% 50% 75% 100%
For the eligible budget, the intensity of the aid in the form of a lost fund may reach as minimum a 100%.
The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations. The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations.
Guarantees:
does not require guarantees
No existen condiciones financieras para el beneficiario.

Additional information about the call

incentive effect: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
non -competitive competitive Very competitive
We do not know the total budget of the line
minimis: Esta línea de financiación NO considera una “ayuda de minimis”. You can consult the regulations here.

other advantages

SME seal: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-HLTH-2021-DISEASE-04 Innovative approaches to enhance poverty-related diseases research in sub-Saharan Africa Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Sin info.
HORIZON-HLTH-2021-DISEASE-04-07 Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada | next call scheduled for the month of
HORIZON-HLTH-2021-DISEASE-04-01 Improved supportive, palliative, survivorship and end-of-life care of cancer patients
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada | next call scheduled for the month of
HORIZON-HLTH-2021-DISEASE-04-03 Innovative approaches to enhance poverty-related diseases research in sub-Saharan Africa
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada | next call scheduled for the month of
HORIZON-HLTH-2021-DISEASE-04-02 Building a European innovation platform for the repurposing of medicinal products
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada | next call scheduled for the month of
HORIZON-HLTH-2021-DISEASE-04-06 Building a European partnership for pandemic preparedness
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada | next call scheduled for the month of